- Home
- EVN vs MAZE Comparison
EVN vs MAZE Comparison
Compare EVN & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVN
- MAZE
- Stock Information
- Founded
- EVN 1998
- MAZE 2018
- Country
- EVN United States
- MAZE United States
- Employees
- EVN N/A
- MAZE N/A
- Industry
- EVN Investment Bankers/Brokers/Service
- MAZE
- Sector
- EVN Finance
- MAZE
- Exchange
- EVN Nasdaq
- MAZE NYSE
- Market Cap
- EVN 410.0M
- MAZE 367.0M
- IPO Year
- EVN N/A
- MAZE 2025
- Fundamental
- Price
- EVN $10.44
- MAZE $9.86
- Analyst Decision
- EVN
- MAZE Strong Buy
- Analyst Count
- EVN 0
- MAZE 3
- Target Price
- EVN N/A
- MAZE $25.67
- AVG Volume (30 Days)
- EVN 101.2K
- MAZE 199.0K
- Earning Date
- EVN 01-01-0001
- MAZE 01-01-0001
- Dividend Yield
- EVN 4.78%
- MAZE N/A
- EPS Growth
- EVN N/A
- MAZE N/A
- EPS
- EVN 0.34
- MAZE 1.25
- Revenue
- EVN N/A
- MAZE $167,500,000.00
- Revenue This Year
- EVN N/A
- MAZE N/A
- Revenue Next Year
- EVN N/A
- MAZE N/A
- P/E Ratio
- EVN $29.94
- MAZE $7.86
- Revenue Growth
- EVN N/A
- MAZE N/A
- 52 Week Low
- EVN $8.64
- MAZE $6.71
- 52 Week High
- EVN $10.45
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- EVN 62.71
- MAZE N/A
- Support Level
- EVN $10.32
- MAZE N/A
- Resistance Level
- EVN $10.53
- MAZE N/A
- Average True Range (ATR)
- EVN 0.12
- MAZE 0.00
- MACD
- EVN 0.05
- MAZE 0.00
- Stochastic Oscillator
- EVN 83.93
- MAZE 0.00
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.